1. Scrip
  2. >>Business

Stock Watch: Spanners In The Works For Q4 Results

Missed Estimates And Accounting Regulations Could Foul The Pitch

 
• By Andy Smith

While the implications of the US Inflation Reduction Act are the focus of the sector’s concern this year, another regulatory development will impact earnings sooner.

Stock Watch Image, Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

The fourth-quarter and full-year 2022 earnings season for life science companies is just around the corner. This quarter in particular is usually something to look forward to because sales are typically better in the final quarter of the year. Companies might also incorporate the boost in revenues from early January’s list price increases into their full-year financial guidance as they report fourth-quarter sales that benefited from drug wholesalers and big pharmacy groups over-ordering in the fourth quarter in anticipation of those price hikes – just as they did at the start of the pandemic when supply chain disruption was anticipated.

That was in the days when list prices meant more than just determining the out-of-pocket cost for those privately and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Stock Watch

More from Business

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 
• By Alaric DeArment

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Merck & Co. Remains In The BD Game After Verona Takeout

 
• By Jessica Merrill

CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.

Asia Deal Watch: JCR And Alexion Build Upon Existing Gene Therapy Alliances

 
• By Joseph Haas, Lisa Takagi, Sushmita Panda, and Anju Ghangurde

Plus deals involving TandemAI/Perpetual Medicines, Biocytogen/BeOne, Chugai/Gero, CStone/Istituto Gentili, Alembic/Utility, Brii/Joincare, HanchorBio/Henlius, Rakuten/Cyntec and more.